Cabaletta Bio Inc (CABA)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. Its main program, resecabtagene autoleucel, is a fully human CD19-targeted CAR T therapy with a 4-1BB co-stimulatory domain and is being evaluated in Phase 1/2 studies across several autoimmune conditions, including myositis-related disorders, lupus, multiple sclerosis, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis. The company is also advancing DSG3-CAART, a Phase 1 candidate for mucosal pemphigus vulgaris, and MuSK-CAART, a Phase 1 therapy for MuSK antibody-positive myasthenia gravis. Cabaletta Bio has research and development collaborations with the University of Pennsylvania, the Children’s Hospital of Philadelphia, Nanjing IASO Biotherapeutics, Oxford Biomedica, Autolus Holdings (UK) Limited, and WuXi Advanced Therapies. Founded in 2017 and based in Philadelphia, Pennsylvania, it was previously known as Tycho Therapeutics, Inc.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.